IL-6   

GtoPdb Ligand ID: 4998

Synonyms: B-cell stimulatory factor 2 | CTL differentiation factor | hybridoma growth factor | interferon β2 | interleukin-6
Comment: IL-6 is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. It is the originating member of a family of related cytokines that include IL-11, oncostatin M (OSM), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine factor 1/B-cell stimulating factor 3 (NNT-1), neuropoietin (NPN), IL-27, and IL-31 [11]. IL-6 is produced by T and B cells, macrophages, dendritic cells, and non-immune cells such as fibroblasts, endothelial cells, glial cells, keratinocytes, and placental syncytio- and extravillous trophoblasts.
The receptors for these cytokines (except IL-31) share a common signal transducing subunit gp130 (IL6ST).
IL-6 is a critical regulator of the immune system and has been widely implicated in autoimmune disease, infection responses and in the regulation of metabolic, regenerative, and neural processes.
Species: Human
References
1. Chen Y, Gardner D, Knight DM, Lark MW, Liang B, Shealy DJ, Song X-yR, Stojanovic-Susulic V, Sweet RW, Tam SH et al.. (2009)
Anti-il-6 antibodies, compositions, methods and uses.
Patent number: US7560112. Assignee: Applied Molecular Evolution, Inc., Centocor Ortho Biotech Inc.. Priority date: 29/04/2005. Publication date: 14/07/2009.
2. Engler H, Brendt P, Wischermann J, Wegner A, Röhling R, Schoemberg T, Meyer U, Gold R, Peters J, Benson S et al.. (2017)
Selective increase of cerebrospinal fluid IL-6 during experimental systemic inflammation in humans: association with depressive symptoms.
Mol. Psychiatry, 22 (10): 1448-1454. [PMID:28138158]
3. Ferreira MA, Matheson MC, Duffy DL, Marks GB, Hui J, Le Souëf P, Danoy P, Baltic S, Nyholt DR, Jenkins M et al.. (2011)
Identification of IL6R and chromosome 11q13.5 as risk loci for asthma.
Lancet, 378 (9795): 1006-14. [PMID:21907864]
4. Garbers C, Heink S, Korn T, Rose-John S. (2018)
Interleukin-6: designing specific therapeutics for a complex cytokine.
Nat Rev Drug Discov, 17 (6): 395-412. [PMID:29725131]
5. Garcia-Martinez L, Jensen AEC, Olson K, Dutzar B, Ojala E, Kovacevich B, Latham J, Smith JTL. (2011)
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies.
Patent number: US8062864. Assignee: Alderbio Holdings Llc. Priority date: 21/05/2007. Publication date: 22/11/2011.
6. Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C et al.. (2014)
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.
Ann. Rheum. Dis., 73 (9): 1607-15. [PMID:24641941]
7. Giles-Komar J, Knight D, Peritt D, Trikha M. (2007)
Anti-IL-6 antibodies, compositions, methods and uses.
Patent number: US7291721. Assignee: Centocor, Inc.. Priority date: 14/11/2001. Publication date: 06/11/2007.
8. Morjaria JB, Babu KS, Vijayanand P, Chauhan AJ, Davies DE, Holgate ST. (2011)
Sputum IL-6 concentrations in severe asthma and its relationship with FEV1.
Thorax, 66 (6): 537. [PMID:20880874]
9. Rose-John S, Conaris Research Institute AG. (2001)
Fusion proteins comprising two soluble gp130 molecules.
Patent number: EP1148065. Assignee: Conaris Research Institute AG. Priority date: 21/04/2000. Publication date: 24/10/2001.
10. Rose-John S, Hipp E, Lenz D, Legrés LG, Korr H, Hirano T, Kishimoto T, Heinrich PC. (1991)
Structural and functional studies on the human interleukin-6 receptor. Binding, cross-linking, internalization, and degradation of interleukin-6 by fibroblasts transfected with human interleukin-6-receptor cDNA.
J. Biol. Chem., 266 (6): 3841-6. [PMID:1995637]
11. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. (2011)
The pro- and anti-inflammatory properties of the cytokine interleukin-6.
Biochim. Biophys. Acta, 1813 (5): 878-88. [PMID:21296109]
12. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al.. (2014)
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
MAbs, 6 (3): 774-82. [PMID:24670876]
13. Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, Vermeulen J, Kent JM, Singh J, Drevets WC et al.. (2017)
The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Brain Behav. Immun., 66: 156-164. [PMID:28676350]
14. Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, Shiozawa K, Tsukano M, Wei JC, Shao J et al.. (2016)
Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial.
Mod Rheumatol, 26 (1): 15-23. [PMID:26358841]
15. Uddin M, Lau LC, Seumois G, Vijayanand P, Staples KJ, Bagmane D, Cornelius V, Dorinsky P, Davies DE, Djukanović R. (2013)
EGF-induced bronchial epithelial cells drive neutrophil chemotactic and anti-apoptotic activity in asthma.
PLoS ONE, 8 (9): e72502. [PMID:24039773]
16. Yokoyama A, Kohno N, Fujino S, Hamada H, Inoue Y, Fujioka S, Ishida S, Hiwada K. (1995)
Circulating interleukin-6 levels in patients with bronchial asthma.
Am. J. Respir. Crit. Care Med., 151 (5): 1354-8. [PMID:7735584]